Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
hVEGF-A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| hVEGF-A | GENETIC | - |
Inclusion Criteria: * Have a clinical diagnosis of Diabetes Mellitus Type I or II for at least 12 months prior to the study. * Have received a diagnosis of mild to moderate sensori-motor diabetic neuropathy from a neurologist (a doctor who specializes in disorders of the nervous system) or endocrin...
hVEGF-A is an investigational gene therapy being studied for the treatment of diabetic neuropathy. It is designed to deliver the vascular endothelial growth factor A gene to promote nerve health. The therapy is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
hVEGF-A is being developed by Sangamo Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol SGMO. The company is conducting clinical research to evaluate the safety and potential efficacy of this gene therapy for diabetic neuropathy.
hVEGF-A is in Phase 1 clinical development. A Phase 1 trial has been completed, involving 12 participants with diabetic neuropathy. The therapy remains investigational and is not yet approved for commercial use.
hVEGF-A has been studied in one clinical trial, identified as NCT00110500, titled "Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy." This Phase 1 study was completed in the United States and enrolled 12 adults aged 18 years and older.
Yes, hVEGF-A is the same as SB-509-0401. The clinical trial NCT00110500 refers to the therapy as SB-509-0401, which is the investigational name used in the study for hVEGF-A in diabetic neuropathy.